Invention Grant
- Patent Title: Expression control using a regulatable intron
-
Application No.: US16640434Application Date: 2018-08-22
-
Publication No.: US11492618B2Publication Date: 2022-11-08
- Inventor: Graham Whyteside
- Applicant: ASKLEPIOS BIOPHARMACEUTICAL, INC.
- Applicant Address: US NC RTP
- Assignee: ASKLEPIOS BIOPHARMACEUTICAL, INC.
- Current Assignee: ASKLEPIOS BIOPHARMACEUTICAL, INC.
- Current Assignee Address: US NC RTP
- Agency: Nixon Peabody LLP
- Agent Ronald I. Eisenstein; Jeanne Jodoin
- Priority: GB1713545 20170823
- International Application: PCT/GB2018/052387 WO 20180822
- International Announcement: WO2019/038544 WO 20190228
- Main IPC: C07H21/02
- IPC: C07H21/02 ; C12N15/113 ; A61K48/00 ; C12N15/85

Abstract:
The present invention relates to the use of a regulatory nucleic acid sequences that are able to regulate gene expression in eukaryotic cells and which are responsive to the unfolded protein response (UPR). There are disclosed regulatable introns and UPR-inducible promoters, which are able to regulate gene expression. There are also disclosed recombinant expression constructs comprising such regulatory nucleic acid sequences, whereby expression of the encoded expression product can be induced by invoking the unfolded protein response (UPR) in a eukaryotic cell containing the construct, methods of using such constructs and associated vectors, cells and suchlike.
Information query